The Community Health Center of the New River Valley and the University of Virginia Cancer Center partnered to boost southwest Virginia’s colorectal cancer screening rate by mailing at-home test kits to patients.
University of Texas Southwestern Moncrief Cancer Institute debuted its second Mobile Screening Clinic prior to the Tarrant County Commissioners Court meeting.
Regeneron Science Talent Search top three finalists, Thomas Cong, Achyuta Rajaram and Michelle Wei.Achyuta Rajaram, a 17-year-old high school student from Exeter, NH, won $250,000 in a first-place award in the Regeneron Science Talent Search 2024.
The phase III CheckMate-9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma who have not received prior systemic therapy met its primary endpoint of improved overall survival, compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis.
A novel treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a phase III trial co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.
Positive results from the EMERALD-1 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with hepatocellular carcinoma eligible for embolization.
A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.
Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to enhance immunotherapy effects against malignant tumors.
Royal College of Surgeons in Ireland preclinical research found that venetoclax, a medication currently approved for leukemia, may have benefits for patients with multiple myeloma when used in combination with another drug—a demethylase inhibitor called 5-azacytidine. This discovery offers a new avenue of treatment options for the currently incurable disease.
Researchers from the University of Southern California found a genetic variant contributing to disparities in childhood leukemia risk. The variant, located on the IKZF1 gene, helps explain why Hispanic/Latino children face a higher risk of acute lymphoblastic leukemia and offers insights about what causes the disease.
